Phenylindenone isomers as divergent modulators of p38α MAP kinase

被引:4
作者
Cappelli, Andrea [1 ,2 ]
Nannicini, Chiara [1 ,2 ]
Chelini, Alessia [1 ,2 ]
Paolino, Marco [1 ,2 ]
Giuliani, Germano [1 ,2 ]
Anzini, Maurizio [1 ,2 ]
Giordani, Antonio [3 ]
Sabatini, Chiara [3 ]
Caselli, Gianfranco [3 ]
Mennuni, Laura [3 ]
Makovec, Francesco [3 ]
Giorgi, Gianluca [1 ,2 ]
Vomero, Salvatore [1 ,2 ]
Menziani, Maria Cristina [4 ]
机构
[1] Univ Siena, Dipartimento Biotecnol Chim & Farm, Via A Moro 2, I-53100 Siena, Italy
[2] Univ Siena, European Res Ctr Drug Discovery & Dev, Via A Moro 2, I-53100 Siena, Italy
[3] Rottapharm Biotech Srl, Via Valosa 3, I-20900 Monza, Italy
[4] Univ Modena & Reggio Emilia, Dipartimento Sci Chim & Geol, Via Campi 103, I-41125 Modena, Italy
关键词
MAPK; Kinases; Synthesis; Docking; P38; INHIBITORS; DISEASE; ACTIVATION; SUBSTRATE; MECHANISM; DYNAMICS; COMPLEX; TARGET; BETA;
D O I
10.1016/j.bmcl.2016.10.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Two new fluorophenylindenone derivatives were designed as potential p38 alpha, MAPK modulators by preserving the key interactions of the vicinal pyridine/fluorophenyl pharmacophore with the enzyme protein. Interestingly, these two fluorophenylindenone isomers showed divergent activities, with compound 6 behaving as an inhibitor and 5 as a putative activator. These results were rationalized by docking studies and molecular dynamics simulations in terms of stabilization of DFG loop, by compound 5 in a conformation more accessible to phosphorylation. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5160 / 5163
页数:4
相关论文
共 18 条
[1]   A Comprehensive Structural Overview of p38 MAPK in Complex with TypeI Inhibitors [J].
Astolfi, Andrea ;
Iraci, Nunzio ;
Manfroni, Giuseppe ;
Barreca, Maria Letizia ;
Cecchetti, Violetta .
CHEMMEDCHEM, 2015, 10 (06) :957-969
[2]   New inhibitors of p38 kinase [J].
Boehm, JC ;
Adams, JL .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (01) :25-37
[3]   The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs) [J].
Clerk, A ;
Sugden, PH .
FEBS LETTERS, 1998, 426 (01) :93-96
[4]   Insights into MAPK p38α DFG flip mechanism by accelerated molecular dynamics [J].
Filomia, Federico ;
De Rienzo, Francesca ;
Menziani, M. Cristina .
BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (18) :6805-6812
[5]   Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease [J].
Fisk, Marie ;
Gajendragadkar, Parag R. ;
Maeki-Petaejae, Kaisa M. ;
Wilkinson, Ian B. ;
Cheriyan, Joseph .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (03) :155-165
[6]  
Foster ML, 2000, DRUG NEWS PERSPECT, V13, P488
[7]  
Hale KK, 1999, J IMMUNOL, V162, P4246
[8]   The Stress Kinase p38α as a Target for Cancer Therapy [J].
Igea, Ana ;
Nebreda, Angel R. .
CANCER RESEARCH, 2015, 75 (19) :3997-4002
[9]   Characterization of the structure and function of a new mitogen-activated protein kinase (p38 beta) [J].
Jiang, Y ;
Chen, CH ;
Li, ZJ ;
Guo, W ;
Gegner, JA ;
Lin, SC ;
Han, JH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (30) :17920-17926
[10]   Novel homologues of CSBP/p38 MAP kinase: Activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles [J].
Kumar, S ;
McDonnell, PC ;
Gum, RJ ;
Hand, AT ;
Lee, JC ;
Young, PR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 235 (03) :533-538